Prognostic impact of pretreatment cell-free DNA concentration in newly diagnosed peripheral T-cell lymphomas

Br J Haematol. 2024 May;204(5):1752-1756. doi: 10.1111/bjh.19280. Epub 2024 Jan 4.

Abstract

Peripheral T-cell lymphomas (PTCLs) have a poor prognosis and, to date, there are no reliable predictive biomarkers of response. In this work we explored the prognostic impact of cell-free DNA (cfDNA) concentration in 75 newly diagnosed patients enrolled in a prospective multicenter study. Pre-treatment cfDNA was strongly associated with clinical risk factors and was identified as a superior predictor for shorter progression-free survival in multivariable analysis, outweighing canonical risk parameters. Furthermore, we identified a cfDNA value above which survival worsens. In conclusion, pre-treatment cfDNA concentration represents an easily usable predictive biomarker that is highly associated with survival of PTCL patients.

Keywords: DNA prognosis; T‐cell lymphoma; haematological malignancies; prognostic factors.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers, Tumor / blood
  • Cell-Free Nucleic Acids* / blood
  • Female
  • Humans
  • Lymphoma, T-Cell, Peripheral* / blood
  • Lymphoma, T-Cell, Peripheral* / diagnosis
  • Lymphoma, T-Cell, Peripheral* / genetics
  • Lymphoma, T-Cell, Peripheral* / mortality
  • Male
  • Middle Aged
  • Prognosis
  • Prospective Studies

Substances

  • Cell-Free Nucleic Acids
  • Biomarkers, Tumor